Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04540120
Recruitment Status : Recruiting
First Posted : September 7, 2020
Last Update Posted : January 26, 2022
Sponsor:
Collaborator:
CTI Clinical Trial and Consulting Services
Information provided by (Responsible Party):
Olatec Therapeutics LLC

Tracking Information
First Submitted Date  ICMJE August 13, 2020
First Posted Date  ICMJE September 7, 2020
Last Update Posted Date January 26, 2022
Actual Study Start Date  ICMJE September 25, 2020
Estimated Primary Completion Date June 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 12, 2021)
Proportion of subjects with clinical deterioration [ Time Frame: Day 15 ]
Clinical deterioration is defined as having any COVID-19-related hospitalization after enrollment or both (1) worsening or persistence of shortness of breath and (2) oxygen saturation less than 92% on room air at sea level or need for supplemental oxygen to achieve oxygen saturation of 92% or greater.
Original Primary Outcome Measures  ICMJE
 (submitted: September 3, 2020)
Proportion of subjects with complete resolution of fever symptoms and shortness of breath [ Time Frame: Day 15 ]
Proportion of subjects with complete resolution of fever symptoms (feeling feverish, chills, shivering and/or sweating) and shortness of breath by Day 15
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 12, 2021)
  • Proportion of subjects with complete resolution of fever symptoms and shortness of breath [ Time Frame: Day 8, Day 15, Day 29, Day 45 ]
    Complete resolution is defined as having a symptom described as "absent" on the subject diary with no return of the symptom before Day 45.
  • Cumulative incidence of SAEs [ Time Frame: Day 45 ]
    Evaluate the cumulative incidence of SAEs of dapansutrile relative to placebo
  • Cumulative incidence of Grade 3 and Grade 4 Adverse Events [ Time Frame: Day 45 ]
    Evaluate the cumulative incidence of Grade 3 and Grade 4 Adverse Events of dapansutrile relative to placebo
  • Discontinuation or temporary suspension of participation [ Time Frame: Day 45 ]
    Evaluate the cumulative incidence of discontinuation or temporary suspension (for any reason) of dapansutrile relative to placebo
  • Changes in white cell count [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in white cell count of dapansutrile relative to placebo over time
  • Changes in hemoglobin [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in hemoglobin of dapansutrile relative to placebo over time
  • Changes in platelets [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in platelets of dapansutrile relative to placebo over time
  • Changes in creatinine [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in creatinine of dapansutrile relative to placebo over time
  • Changes in glucose [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in glucose of dapansutrile relative to placebo over time
  • Changes in total bilirubin [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in total bilirubin of dapansutrile relative to placebo over time
  • Changes in ALT [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in ALT of dapansutrile relative to placebo over time
  • Changes in AST [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in AST of dapansutrile relative to placebo over time
  • Incidence of new infection that occurs during the study [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in incidence of new infection that occurs during the study of dapansutrile relative to placebo
  • Incidence of opportunistic infections [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in incidence of opportunistic infections of dapansutrile relative to placebo
  • Time to clinical improvement [ Time Frame: Baseline/Day 1 to Day 15 ]
    Time to clinical improvement in fever symptoms and shortness of breath
  • Time to sustained absence of fever [ Time Frame: Baseline/Day 1 to Day 15 ]
    Time to sustained absence of fever, defined as at least 2 days since last temperature measurement of ≥ 38˚C (100.4°F)
  • Clinical improvement in symptoms relevant to COVID 19 [ Time Frame: Day 15 ]
    Proportion of subjects who experience clinical improvement in symptoms relevant to COVID 19 (e.g., cough, diarrhea, vomiting)
  • Incidence of hospitalization, supplemental oxygen, mechanical ventilation, or death before Day 15 [ Time Frame: Day 15 ]
    Incidence of subjects meeting the composite endpoint of subjects requiring hospitalization (hospitalization is defined as ≥ 24 hours of acute care), supplemental oxygen, mechanical ventilation, or who die
  • Duration of hospitalization, supplemental oxygen or mechanical ventilation before Day 15 [ Time Frame: Day 15 ]
    Duration of incidences of subjects meeting the composite endpoint of subjects requiring hospitalization (hospitalization is defined as ≥ 24 hours of acute care), supplemental oxygen or mechanical ventilation
  • Clinical improvement in symptoms [ Time Frame: Baseline/Day 1 to Day 15 ]
    Proportion of subjects who experience clinical improvement in symptoms by Day 15, defined as a reduction of two or more points on the WHO Ordinal Scale for Clinical Improvement (lowest score between Baseline Visit/Day 1 and Day 15)
  • Improvement in oxygenation [ Time Frame: Baseline/Day 1 to Day 15 ]
    Improvement in oxygenation over the course of the study and maintenance of this effect
  • Change in ALT [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in AST
  • Change in AST [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in AST
  • Change in blood glucose [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in blood glucose
  • Change in Erythrocyte Sedimentation Rate (ESR) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Erythrocyte Sedimentation Rate (ESR)
  • Change in Hemoglobin A1c (HbA1C) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Hemoglobin A1c (HbA1C)
  • Change in Lactate dehydrogenase (LDH) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Lactate dehydrogenase (LDH)
  • Change in Lymphocyte, Absolute count [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Lymphocyte, Absolute count
  • Change in Monocyte, Absolute count [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Monocyte, Absolute count
  • Change in Neutrophils, Absolute count [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Neutrophils, Absolute count
  • Change in Eosinophil, Absolute count [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Eosinophil, Absolute count
  • Change in CRP [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in CRP
  • Change in D-Dimer [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in D-Dimer
  • Change in Ferritin [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Ferritin
  • Change in Fibrinogen [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Fibrinogen
  • Change in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR)
  • Change in IL-1β [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in IL-1β
  • Change in IL-6 [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in IL-6
  • Change in IL-18 [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in IL-18
  • Change in granulocyte colony-stimulating factor (G-CSF) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in granulocyte colony-stimulating factor (G-CSF)
  • Change in interferon-γ-induced protein 10 (IP-10) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in interferon-γ-induced protein 10 (IP-10)
  • Change in C3a [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in C3a
Original Secondary Outcome Measures  ICMJE
 (submitted: September 3, 2020)
  • Cumulative incidence of SAEs [ Time Frame: Day 45 ]
    Evaluate the cumulative incidence of SAEs of dapansutrile relative to placebo
  • Cumulative incidence of Grade 3 and Grade 4 Adverse Events [ Time Frame: Day 45 ]
    Evaluate the cumulative incidence of Grade 3 and Grade 4 Adverse Events of dapansutrile relative to placebo
  • Discontinuation or temporary suspension of participation [ Time Frame: Day 45 ]
    Evaluate the cumulative incidence of discontinuation or temporary suspension (for any reason) of dapansutrile relative to placebo
  • Changes in white cell count [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in white cell count of dapansutrile relative to placebo over time
  • Changes in hemoglobin [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in hemoglobin of dapansutrile relative to placebo over time
  • Changes in platelets [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in platelets of dapansutrile relative to placebo over time
  • Changes in creatinine [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in creatinine of dapansutrile relative to placebo over time
  • Changes in glucose [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in glucose of dapansutrile relative to placebo over time
  • Changes in total bilirubin [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in total bilirubin of dapansutrile relative to placebo over time
  • Changes in ALT [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in ALT of dapansutrile relative to placebo over time
  • Changes in AST [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in AST of dapansutrile relative to placebo over time
  • Incidence of new infection that occurs during the study [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in incidence of new infection that occurs during the study of dapansutrile relative to placebo
  • Incidence of opportunistic infections [ Time Frame: Day 8, Day 15 ]
    Evaluate changes in incidence of opportunistic infections of dapansutrile relative to placebo
  • Complete resolution of fever symptoms and shortness of breath [ Time Frame: Day 8, Day 29 and Day 45 ]
    Proportion of subjects who experience clinical resolution of fever symptoms and shortness of breath
  • Time to clinical improvement [ Time Frame: Baseline/Day 1 to Day 15 ]
    Time to clinical improvement in fever symptoms and shortness of breath
  • Time to sustained absence of fever [ Time Frame: Baseline/Day 1 to Day 15 ]
    Time to sustained absence of fever, defined as at least 2 days since last temperature measurement of ≥ 38˚C (100.4°F)
  • Clinical improvement in symptoms relevant to COVID 19 [ Time Frame: Day 15 ]
    Proportion of subjects who experience clinical improvement in symptoms relevant to COVID 19 (e.g., cough, diarrhea, vomiting)
  • Incidence of composite endpoint of hospitalization, supplemental oxygen, mechanical ventilation, or death [ Time Frame: Day 45 ]
    Incidence of subjects meeting the composite endpoint of subjects requiring hospitalization (hospitalization is defined as ≥ 24 hours of acute care), supplemental oxygen, mechanical ventilation, or who die
  • Clinical improvement in symptoms [ Time Frame: Baseline/Day 1 to Day 15 ]
    Proportion of subjects who experience clinical improvement in symptoms by Day 15, defined as a reduction of two or more points on the WHO Ordinal Scale for Clinical Improvement (lowest score between Baseline Visit/Day 1 and Day 15)
  • Improvement in oxygenation [ Time Frame: Baseline/Day 1 to Day 15 ]
    Improvement in oxygenation over the course of the study and maintenance of this effect
  • Change in ALT [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in AST
  • Change in AST [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in AST
  • Change in blood glucose [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in blood glucose
  • Change in Erythrocyte Sedimentation Rate (ESR) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Erythrocyte Sedimentation Rate (ESR)
  • Change in Hemoglobin A1c (HbA1C) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Hemoglobin A1c (HbA1C)
  • Change in Lactate dehydrogenase (LDH) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Lactate dehydrogenase (LDH)
  • Change in Lymphocyte, Absolute count [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Lymphocyte, Absolute count
  • Change in Monocyte, Absolute count [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Monocyte, Absolute count
  • Change in Neutrophils, Absolute count [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Neutrophils, Absolute count
  • Change in Eosinophil, Absolute count [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Eosinophil, Absolute count
  • Change in CRP [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in CRP
  • Change in D-Dimer [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in D-Dimer
  • Change in Ferritin [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Ferritin
  • Change in Fibrinogen [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Fibrinogen
  • Change in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in Partial Thromboplastin Time (PTT) and International Normalized Ratio (INR)
  • Change in IL-1β [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in IL-1β
  • Change in IL-6 [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in IL-6
  • Change in IL-18 [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in IL-18
  • Change in granulocyte colony-stimulating factor (G-CSF) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in granulocyte colony-stimulating factor (G-CSF)
  • Change in interferon-γ-induced protein 10 (IP-10) [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in interferon-γ-induced protein 10 (IP-10)
  • Change in C3a [ Time Frame: Baseline/Day 1 to Day 15 ]
    Assess and compare change from Baseline in C3a
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
Official Title  ICMJE A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
Brief Summary

The purpose of this study is to assess the safety and efficacy of orally administered NLRP3 inhibitor, dapansutrile, for the treatment of moderate COVID-19 symptoms and early cytokine release syndrome (CRS) in patients with confirmed SARS-CoV-2 infection and moderate symptoms.

Coronavirus disease 2019 (COVID-19) is caused by infection from a new strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is characterized by fever, cough and shortness of breath, which in certain patients can lead to systemic organ failure and mortality.

The data show that SARS-CoV-2 activates the innate immune signaling sensor NLRP3. Activation of NLRP3 initiates the cytokine release syndrome (CRS), which includes the production of primary cytokine, IL-1, triggering an intense inflammatory response that is prevalent in symptomatic COVID-19 patients. When CRS advances further to a fulminant 'cytokine storm', the data show that respiratory distress syndrome and multiple-organ failure take place.

A specific inhibitor of NLRP3, dapansutrile may reduce or prevent the hyperinflammation associated with CRS by inhibiting the production of IL-1β early to arrest the progression to a severe 'cytokine storm.' The end result would be a reduction in the need for COVID-19 patients to receive intensive medical treatment, allowing for fewer hospitalizations, administration of mechanical ventilation and deaths.

Detailed Description

This is a Phase 2, randomized, double-blind, placebo-controlled study evaluating dapansutrile versus placebo. Approximately 80 subjects randomized 1:1 (40 dapansutrile, 40 placebo) are planned to be enrolled.

At the Screening/Baseline/Day 1 Visit, subjects will provide informed consent, be screened for eligibility, and be randomized/enrolled into the study. Subjects will also receive the first dose of study drug at this visit once study eligibility has been confirmed, and the second dose of study drug will be taken approximately 12 hours after the first dose. Study drug will be continued twice daily (morning and evening doses) through Day 14.

The trial duration will be approximately 45 days for all subjects enrolled, with assessments as follows: Screening/Baseline/Day 1, Day 4 (±1 day), Day 8 (±1 day), Day 15 (±1 day), Day 29 (±3 days), and Day 45 (± 3 days). The Day 29 and Day 45 follow-up visits will be conducted virtually via the institution's telehealth process.

Each subject will be asked to maintain two paper diaries at home daily for the first 14 days: a dosing diary and a subject diary. The dosing diary will be used to record the number of capsules taken each morning and evening. The subject diary will be used to record temperature, oxygen levels, COVID-19 symptoms, and overall health (using the prior 24-hour period for parameters requiring subject recall). The set of questions used in the subject diary will also be administered to the subjects at the Screening/Baseline/Day 1 Visit (pre-dose), Day 15, Day 29, and Day 45 visits. Each subject will be provided a no-contact thermometer and a hand-held pulse oximeter at the Screening/Baseline/Day 1 Visit for home use.

At Day 29 and Day 45, additional assessments of safety and clinical activity will occur. The Day 29 and Day 45 follow-up visits will be conducted virtually via the sites' telehealth process.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Subjects will be assigned to receive either dapansutrile capsules or placebo capsules in a 1:1 ratio.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:
This is a randomized, blinded, placebo-controlled study. Treatment allocation (to active or placebo treatment groups) will be blinded to all study participants, personnel, and investigators. Only the drug labeling personnel, unblinded pharmacist and DMC members may be unblinded to the treatment assignment. Also, in the event of an emergency, an unblinding envelope can be opened unmasking the treatment assignment to the PI.
Primary Purpose: Treatment
Condition  ICMJE
  • Covid19
  • Cytokine Release Syndrome
Intervention  ICMJE
  • Drug: dapansutrile capsules
    Hard opaque capsules containing 250 mg of API.
    Other Name: OLT1177 capsules
  • Drug: placebo capsules
    Hard opaque capsules containing 0 mg of API.
Study Arms  ICMJE
  • Experimental: dapansutrile capsules
    Subjects will receive 4 x 250mg dapansutrile capsules BID for 14 days with an initial (first) dose of 8 x 250mg (2000 mg) administered at the study site on Day 1 (Day 1 dose may be 3000 mg).
    Intervention: Drug: dapansutrile capsules
  • Placebo Comparator: placebo capsules
    Subjects will receive 4 placebo capsules BID for 14 days with an initial (first) dose of 8 capsules administered at the study site on Day 1.
    Intervention: Drug: placebo capsules
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 3, 2020)
80
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2022
Estimated Primary Completion Date June 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male and female subjects ≥ 18 years of age;
  2. SARS-CoV-2-positive, confirmed by Food and Drug Administration (FDA)- or European Medicines Agency (EMA)-authorized COVID-19 test ≤ 7 days prior to randomization;
  3. Less than or equal to 7 days from first symptom onset to randomization;
  4. Subjects with moderate COVID-19 consistent with the definition of "moderate" as set forth by the February 2021 FDA Guidance for Industry: COVID-19: Developing Drugs and Biological Products for Treatment or

    Prevention (FDA, 2021) who at the Screening/Baseline/Day 1 Visit:

    1. have felt feverish within the past 24 hours,
    2. have an SpO2 > 93% on room air at sea level when sitting, and
    3. meet at least one of the following criteria: i). Respiratory rate: ≥ 20 breaths/minute, when the subject is sitting, ii). SpO2: ≤ 96% on room air at sea level, when the subject is sitting, iii). Shortness of breath: with exertion, not requiring oxygen, or vi). Heart rate: ≥ 90 beats/minute, when the subject is sitting;
  5. If all the criteria in Inclusion 4c are met, subject must possess at least one of the following high-risk conditions known to have an underlying increased level of cytokine production; otherwise, at least two of these high-risk conditions must be met:

    1. 70 years or more of age,
    2. Obesity (BMI ≥ 30 kg/m2),
    3. Diabetes (type 1 or 2),
    4. Uncontrolled hypertension, defined as diastolic > 100 mm Hg and/or systolic > 150 mm Hg without any current anti-hypertensive medications. At the time of screening if the subject is on anti- hypertensive medication(s) and diastolic or systolic rates are elevated, subject may be enrolled after consultation with the Medical Monitor,
    5. Known respiratory disease (including asthma or chronic obstructive pulmonary disease [COPD]),
    6. Known heart failure (note: subjects with New York Heart Association Class IV congestive heart failure cannot be enrolled per Exclusion Criterion 4), or
    7. Known coronary disease;
  6. Plasma CRP level must be collected at Screening/Baseline/Day 1 Visit;
  7. Acceptable overall medical condition to be safely enrolled in and complete the study (with specific regard to cardiovascular, renal, and hepatic conditions) in the opinion of the Investigator;
  8. Ability to provide written, informed consent prior to initiation of any study- related procedures, and ability in the opinion of the Investigator to understand and comply with all the requirements of the study, which includes abstaining from the use of prohibited medications.
  9. Subject must present with at least moderate symptomatology, based on having symptoms in the prior 24 hours that were uncomfortable and interfered with daily activities or required treatment other than study drug and having at least one of the following symptoms: cough; fatigue; myalgia; diarrhea; vomiting; nausea; headache; sore throat; nasal congestion; rhinorrhea; loss of taste; loss of smell; fainting; or chills, shivering, and/or sweating.

Exclusion Criteria:

  1. Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential, who:

    1. Are or intend to become pregnant (including use of fertility drugs) during the study;
    2. Are nursing (female subjects only);
    3. Are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete.
  2. Evidence of pre-existing or new-onset organ failure;
  3. Evidence of moderate concurrent nervous system, renal, endocrine, or gastrointestinal disease, unrelated to COVID-19 as determined by the Investigator;
  4. Evidence of cardiovascular disease with significant arrhythmia, congestive heart failure (New York Heart Association Class IV), unstable angina, cor pulmonale, or symptomatic pericardial effusion, not related to COVID-19 as determined by the Investigator;
  5. Required use of vasoactive drug support;
  6. History of myocardial infarction in the 6 months prior to the Screening/Baseline/Day 1 Visit;
  7. Evidence of current liver disease, not related to COVID-19 as determined by the investigator;
  8. History or evidence of active tuberculosis (TB) infection at Screening/Baseline/Day 1 Visit or one of the risk factors for tuberculosis such as but not limited or exclusive to:

    1. History of any of the following: residence in a congregate setting (e.g., jail or prison, homeless shelter, or chronic care facility), substance abuse (e.g., injection or non-injection), health-care workers with unprotected exposure to subjects who are at high risk of TB or subjects with TB disease before the identification and correct airborne precautions of the subject or
    2. Close contact (i.e., share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours)) with a person with active pulmonary TB disease within the last 12 months.
  9. History of or currently active primary or secondary immunodeficiency;
  10. Past or present requirement for oxygen (e.g., nasal cannula, proning, mechanical ventilation and/or supplemental oxygen).
  11. Use of any prohibited concomitant medications/therapies over the defined or planned use of any concomitant medications/therapies during the

    Treatment Period, including specifically:

    1. use of ibuprofen or diclofenac
    2. use of colchicine
    3. use of systemic steroids within 30 days of randomization
    4. use of janus kinase (JAK) inhibitors
    5. use of off-label agents (e.g., hydroxychloroquine, remdesivir, dexamethasone) and biologic and oral anti-cytokine agents (e.g., current treatment with adalimumab, infliximab, etanercept, golimumab, certolizumab pegol, tocilizumab, sarilumab, anakinra, canakinumab, rilonacept, baricitinib, tofacitinib, or upadacitinib);

    Note: During the treatment period a patient may meet the criteria for a treatment approved by the FDA specifically for COVID-19 (e.g. remdesivir). In this situation the investigator and medical monitor should confer and take the most appropriate decision for the patient. If possible, the preference would be for the patient to complete the 14 days of dosing before adding on the 2nd treatment. If that is not possible the preference would be for the patient to continue their 14 days on dapansutrile and complete all study related visits.

  12. Known history of renal impairment (e.g., calculated glomerular filtration rate [GFR] < 45 mL/min);
  13. Evidence of malignant disease, or malignancies diagnosed within the previous 5 years (except for local basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured);
  14. History of infection or known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  15. Any other concomitant medical or psychiatric conditions, diseases, or prior surgeries that, in the opinion of the Investigator, would impair the subject from safely participating in the trial and/or completing protocol requirements;
  16. Individuals who have been in a chronic care facility in the past 30 days;
  17. Individuals who are incarcerated;
  18. Participation in any clinical trial and/or use of any investigational product within the immediate 30-day period prior to the Screening/Baseline//Day 1 Visit; or receipt prior to Screening/Baseline/Day 1 Visit or intending to receive during the trial a COVID-19 vaccination.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Clinical Trial Operations +1 833-652-8321 inquiries@olatec.com
Listed Location Countries  ICMJE Netherlands,   Switzerland,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04540120
Other Study ID Numbers  ICMJE OLT1177-10
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Olatec Therapeutics LLC
Study Sponsor  ICMJE Olatec Therapeutics LLC
Collaborators  ICMJE CTI Clinical Trial and Consulting Services
Investigators  ICMJE Not Provided
PRS Account Olatec Therapeutics LLC
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP